Drug Trial Radar · NCT02567656
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Jan 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Sep 2015
Primary completion
Mar 2018
Study completion Dec 10, 2018
Sponsor
- Lead sponsor
- Rhizen Pharmaceuticals SAIndustry
- Sponsor type
- Industry
- First posted
- Oct 5, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
Conditions
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell, Cutaneous
Interventions
RP6530Drug
Tablet starting at 200 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of RP6530Time frame: 28 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Chao Family Comprehensive Cancer Center University of California Irvine
Orange, California
University of Colorado Cancer Center
Aurora, Colorado
Emory University School of Medicine
Atlanta, Georgia
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
University Hospitals Cleveland Medical Center
Cleveland, Ohio
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.